![Moderna pharmaceutical and biotechnology company's CEO Stephane Bancel poses.](https://www.statnews.com/wp-content/uploads/2023/03/GettyImages-1244666141-645x645.jpg)
Moderna CEO Stéphane Bancel is starting to reap gargantuan gains from the stock he first got when he started with the company a decade ago, although nearly all of this chunk of his fortune remains earmarked for charities.
Bancel made $398 million in 2022 based on the actual realized gains of stock that was exercised and sold, according to STAT’s calculations from Moderna’s annual compensation disclosure filed this week. The more commonly reported compensation figure, $19.4 million, is less accurate and does not factor in the value Bancel actually received from his stock.
The pay package is likely to be one of the largest in health care for 2022. Bancel is still “committed to contributing the after-tax proceeds from the option exercise to charitable causes,” the company said in the filing.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.